Clinical Scorecard: Irradiation of Tumors Enhances Antigen Presentation by Dendritic Cells, Improving CAR T Cell Longevity and Effectiveness in Lung Metastases
At a Glance
Category
Detail
Condition
Lung Metastases
Key Mechanisms
Irradiation enhances CAR T cell cytotoxicity and persistence by sensitizing tumors and improving antigen presentation by dendritic cells.
Target Population
Patients with extensive solid tumors, specifically lung cancer.
Care Setting
Clinical trials and experimental treatment settings.
Key Highlights
Irradiation of tumors improves CAR T cell efficacy against lung tumors.
8 Gy of thoracic radiotherapy enhances CAR T cell cytotoxicity without causing lung injury.
Irradiated tumors show significantly reduced tumor burden and improved survival in treated mice.
CAR T cells exhibit prolonged activity in irradiated tumors, with increased persistence.
Dendritic cells play a crucial role in expanding CAR T cells through antigen presentation.
Guideline-Based Recommendations
Diagnosis
Utilize imaging techniques to assess tumor burden in lung cancer patients.
Management
Consider thoracic radiotherapy as a palliative treatment to enhance CAR T cell therapy.
Monitoring & Follow-up
Track tumor bioluminescence and CAR T cell persistence post-treatment.
Risks
Monitor for potential on-target, off-tumor toxicity with CAR T cell therapies.
Patient & Prescribing Data
Patients with advanced lung cancer and extensive solid tumors.
Irradiation prior to CAR T cell infusion may improve treatment outcomes.
Clinical Best Practices
Administer CAR T cells after tumor irradiation to maximize efficacy.
Evaluate the immunosuppressive microenvironment when planning CAR T cell therapies.
by Sophia Navarre, Maki N. Ishibashi, Achuth Nair, Ivan Reyes-Torres, Meriem Belabed, Laszlo Halasz, Matthew D. Park, Raphaël Mattiuz, Merouane Ounadjela, Gertrude Gunset, Jorge Mansilla-Soto, Judith Feucht, Annalisa Cabriolu, Jessica Le Berichel, Alexander Birbrair, Justin Eyquem, Brian D. Brown, Miriam Merad, Michel Sadelain, Jalal Ahmed
